The study was designed to confirm the most effective dose of NTCELL, define any placebo component of the response and further identify the initial target Parkinson’s disease patient sub group.
Efficacy was measured using the Unified Parkinson’s Disease Rating Scale (UPDRS).
Initial data from the 18-month follow up of 18 patients show a statistically significant improvement (p = <0.05) in the UPDRS in the patients who received 80 NTCELL capsules implantation to the putamen on both sides of the brain as compared to the placebo group that received sham surgery.
No benefit was observed when 120 NTCELL capsules were implanted, there being evidence of inflammation which may have compromised efficacy in this group.
Oral ANVS401 Improves Patients’ Motor Skills in Phase 2 Trial
New Clinical Trial Starting: A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD) (REGENERATE-PD)
